True North Appoints Biotechnology Commercial Executive Jeff Ajer to its Board of Directors
Company Adds BioMarin Chief Commercial Officer with Rare Disease Expertise as Independent Board Member
South San Francisco, CA, February 1, 2017 — True North Therapeutics, a clinical stage biotechnology company developing novel product candidates that selectively inhibit the Complement system, today announced that the company has appointed Jeff Ajer, Executive Vice President and Chief Commercial Officer of BioMarin, as an independent director to the company’s board of directors. With more than 20 years of experience building industry-leading commercial organizations, Mr. Ajer brings a seasoned and unique perspective to True North’s Board of Directors.
“We are delighted that Jeff has joined our board,” said Nancy Stagliano, PhD, Chief Executive Officer of True North Therapeutics. “We believe his extensive commercial experience with products for rare diseases, which includes over 11 years at BioMarin where he built the company’s commercial infrastructure and led successful drug launches, will be invaluable as we continue to build a pipeline of innovative medicines designed to treat Complement-mediated rare diseases, including our lead molecule TNT009 where we have demonstrated the potential for a pipeline in a product based on encouraging clinical and preclinical data.”
“True North is making significant progress advancing drug candidates that address a fundamental pathway driving numerous rare diseases,” said Jeff Ajer. “I am looking forward to working with the board and management team as True North accelerates development of its lead product candidate, TNT009, toward late-stage clinical development for Cold Agglutinin Disease and expands its potential in additional Complement-mediated rare diseases.”
Jeff Ajer joined BioMarin in 2005 and is the Executive Vice President and Chief Commercial Officer. He has served as Chief Commercial Officer of Biomarin since 2012. Previously, Mr. Ajer served as BioMarin’s Vice President of Commercial Operations, The Americas, where he had responsibility for commercial operations throughout the Americas and led product marketing, reimbursement, and sales operations for BioMarin. Since joining as one of the first sales and marketing employees, Mr. Ajer has played a leadership role in establishing BioMarin’s successful commercial infrastructure and global footprint, shaped the launches and growth strategies for the company’s three key commercial products for rare diseases, and led commercial planning for late-stage pipeline programs. Prior to BioMarin, Mr. Ajer served as Vice President, Global Transplant Operations at Genzyme Corporation. Mr. Ajer’s experience prior to Genzyme includes roles in sales, marketing and operations at SangStat Medical Corporation and ICN Pharmaceuticals. Mr. Ajer received a B.S. in chemistry and an M.B.A. from the University of California, Irvine.
About True North Therapeutics
True North Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class product candidates for Complement-mediated diseases. The company’s lead product candidate, TNT009, is designed to selectively inhibit a target in the Classical Complement pathway. True North’s antibody drug development is focused on the treatment of certain rare diseases mediated by the Complement system. True North Therapeutics is located in South San Francisco, California. For more information, please visit www.truenorthrx.com.
The Yates Network